溢价246%收购！赛诺菲剑指武田、艾伯维折戟的靶点_老虎社区_美港股上老虎

溢价246%收购！赛诺菲剑指武田、艾伯维折戟的靶点

药时代2025-05-27

正文共2000字 2图预计阅读时间5分钟在2025年5月22日，全球医药巨头赛诺菲（Sanofi）宣布了一项重要决定：以每股8美元现金的价格，总额约4.7亿美元收购Vigil Neuroscience。这一价格显著高于Vigil Neuroscience目前1.15亿美元的市值，溢价高达246%。这次收购的核心在于VG-3927，一种针对骨髓细胞表达触发受体2（TREM2）的口服小分子激动剂，用于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2538281482?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-27 08:05","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2538281482","market":"us","top_or_hot":-1,"title":"溢价246%收购！赛诺菲剑指武田、艾伯维折戟的靶点","media":"药时代","content":"<div>\n<p>正文共2000字 2图预计阅读时间5分钟在2025年5月22日，全球医药巨头赛诺菲（Sanofi）宣布了一项重要决定：以每股8美元现金的价格，总额约4.7亿美元收购Vigil Neuroscience。这一价格显著高于Vigil Neuroscience目前1.15亿美元的市值，溢价高达246%。这次收购的核心在于VG-3927，一种针对骨髓细胞表达触发受体2（TREM2）的口服小分子激动剂，用于...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527094954a6ee2adf&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>溢价246%收购！赛诺菲剑指武田、艾伯维折戟的靶点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n溢价246%收购！赛诺菲剑指武田、艾伯维折戟的靶点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-27 08:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527094954a6ee2adf&s=b><strong>药时代</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>正文共2000字 2图预计阅读时间5分钟在2025年5月22日，全球医药巨头赛诺菲（Sanofi）宣布了一项重要决定：以每股8美元现金的价格，总额约4.7亿美元收购Vigil Neuroscience。这一价格显著高于Vigil Neuroscience目前1.15亿美元的市值，溢价高达246%。这次收购的核心在于VG-3927，一种针对骨髓细胞表达触发受体2（TREM2）的口服小分子激动剂，用于...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527094954a6ee2adf&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1267930490.SGD","symbol_name":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527094954a6ee2adf&s=b","article_id":"2538281482","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250527094954a6ee2adf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2538281482","pubTimestamp":1748304331,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"这意味着，VG-3927作为全球首款用于AD治疗、目前临床进展最快的口服小分子TREM2激动剂，证明了TREM2这条通路用于治疗AD的可行性。VG-3927在此领域的领先优势获得了赛诺菲的青睐。凭借其独特的作用机制、积极的临床数据以及口服剂型所带来的优势，此次收购有望为赛诺菲开辟新的增长点，并为全球阿尔茨海默病患者提供新的治疗希望。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","BK4563":"昨日强势股","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","BK4139":"生物科技","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","VG":"Venture Global, Inc.","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","ABBV":"艾伯维公司","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","BK4588":"碎股","BK4550":"红杉资本持仓","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","PAM":"Pampa Energia S.A.","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","ARIA":"阿里阿德","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","BK4581":"高盛持仓","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC"},"translate_title":"246% premium acquisition! Sanofi's sword targets Takeda and AbbVie's halberds","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VG":0.9,"PAM":1,"ARIA":1,"ABBV":0.9},"content_text":"正文共2000字 2图预计阅读时间5分钟在2025年5月22日，全球医药巨头赛诺菲（Sanofi）宣布了一项重要决定：以每股8美元现金的价格，总额约4.7亿美元收购Vigil Neuroscience。这一价格显著高于Vigil Neuroscience目前1.15亿美元的市值，溢价高达246%。这次收购的核心在于VG-3927，一种针对骨髓细胞表达触发受体2（TREM2）的口服小分子激动剂，用于治疗包括阿尔茨海默病（AD）在内的神经退行性疾病。该药物预计将在今年下半年进入II期临床试验。图片来源：sanofi官网在TREM2靶点中突破重围为何赛诺菲愿意溢价246%收购一家AD新药公司呢？让我们先了解一下它的核心产品吧。口服小分子TREM2激动剂VG-3927旨在增强小胶质细胞对聚集淀粉样蛋白和tau的保护性反应，同时不增加炎症反应。基于其激动剂和正变构调节剂（PAM）的新型作用模式，可能会放大VG-3927在病灶部位的作用，从而强烈调节小胶质细胞并可能增强神经保护。由于VG-3927不与sTREM2结合，与抗体TREM2激动剂相比，该疗法可最大限度地提高受体活化和小胶质细胞功能，这可能会增加其进入AD病灶的机会。此外，VG-3927没有Fc结构域，该结构域与免疫系统中与淀粉样蛋白相关成像异常（ARIA）风险增加相关的元素有关。图片来源：Vigil Neuroscience披露资料在今年年初，Vigil Neuroscience公布了VG-3927用于阿尔茨海默病的一期临床试验结果。VG-3927在患者脑脊液中实现了高达约50%的游离TREM2（sTREM2）显著剂量依赖性降低，且显示出高脑外显率、可耐受的安全性。这意味着，VG-3927作为全球首款用于AD治疗、目前临床进展最快的口服小分子TREM2激动剂，证明了TREM2这条通路用于治疗AD的可行性。值得一提的是，考虑到其他竞争对手如武田与Denali共同开发的单抗NL919、艾伯维与Alector共同开发的单克隆抗体AL002等TREM2靶向药物相继折戟的背景下，VG-3927的积极数据显得尤为突出，对CNS领域的研究者有着借鉴与鼓舞的作用。此外，VG-3927还是TREM2赛道中唯三治疗CNS适应症的临床阶段项目，并取得了积极的临床数据（其余两款为诺华自主研发的单抗VHB937、安进原研、已授权给Vigil的单抗VGL101），这或许也是赛诺菲砸下重金的关键原因。更何况VG-3927还有一个亮点，是以上管线中唯一一款口服小分子TREM2激动剂，可实现每日1次给药。口服剂型将成为AD研发next level近年来，随着Aduhelm、Leqembi以及Donanemab等药物的相继获批，AD药物的研发进入了快速发展阶段。然而，这些新批准的药物在商业化过程中面临着一系列挑战，特别是与输液相关的基础设施需求。例如，Leqembi需要每月两次给药，并且患者必须在专科中心接受输液治疗。目前，在研的AD药物中，上市的口服剂型相对较少。首款FDA批准的口服AD药物是2014年的美金刚/多奈哌齐复方制剂，而直到2024年第二款药物Zunveyl才获得批准。2025年1月8日，康哲宣布获得了Zunveyl在亚洲（除日本）、澳大利亚和新西兰的独家权益，协议总金额达到4000万美元。这一动态表明，尽管存在挑战，但口服AD药物因其便利性和潜在的市场吸引力，正逐渐成为研发的next level。VG-3927在此领域的领先优势获得了赛诺菲的青睐。结语：综上所述，赛诺菲对Vigil Neuroscience的收购标志着其在神经病学领域的关键战略布局，成功将具有潜力的阿尔茨海默病口服小分子药物VG-3927纳入麾下。凭借其独特的作用机制、积极的临床数据以及口服剂型所带来的优势，此次收购有望为赛诺菲开辟新的增长点，并为全球阿尔茨海默病患者提供新的治疗希望。随着VG-3927二期临床试验的推进，其能否实现创新突破并改变AD治疗格局，值得行业持续关注。参考资料：1.https://www.vigilneuro.com/trem22.https://www.sanofi.cn/zh3.https://www.biospace.com/deals/sanofi-buys-vigil-for-470m-upfront-reigniting-a-battered-alzheimers-target4.其他公开资料图片来源：豆包AI突破的力量：这家跨国药企如何用4年成为中国医药创新 “造氧机”？2025-05-26中国创新药出海排行榜（征求意见稿）2025-05-25超越·盈领｜2025诺和诺德首届肥胖症论坛璀璨落幕，擘画肥胖管理新篇章2025-05-24版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢!药时代官方网站:www.drugtimes.cn联系方式:电话:13651980212微信:27674131邮箱:contact@drugtimes.cn点击这里，查看更多精彩！","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}